Genmab — Juli 2018
-
Jeg er med på safetyproblemet, men konklusionen er stadigvæk, at "The mechanism of immune resistance to anti-PDL1/PD-1
therapy caused by CD38 provides an evident rationale for recruitment of
cancer patients for clinical trials of anti-CD38 in combination with anti-PD-L1/PD-1 to
prevent therapy resistance and further enhance anti-tumor efficacy." -
God morgen

-
god morgen

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind